RxSight Management
Management criteria checks 3/4
RxSight's CEO is Ron Kurtz, appointed in Jan 2016, has a tenure of 8.92 years. total yearly compensation is $3.08M, comprised of 20.6% salary and 79.4% bonuses, including company stock and options. directly owns 2.05% of the company’s shares, worth $29.68M. The average tenure of the management team and the board of directors is 4.3 years and 3.4 years respectively.
Key information
Ron Kurtz
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 20.6% |
| CEO tenure | 9yrs |
| CEO ownership | 2.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Dec 06
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$3m | US$633k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$563k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$445k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$17m |
| Dec 31 2020 | US$741k | US$310k | US$3m |
Compensation vs Market: Ron's total compensation ($USD3.08M) is below average for companies of similar size in the US market ($USD5.42M).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
CEO
Ron Kurtz (61 yo)
9yrs
Tenure
US$3,081,597
Compensation
Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9yrs | US$3.08m | 2.05% $ 29.7m | |
| Co-President & Chief Commercial Officer | 9.6yrs | US$1.65m | 0.76% $ 11.0m | |
| Co-President & Chief Financial Officer | 7.9yrs | US$1.89m | 0.076% $ 1.1m | |
| Co-President & Chief Operating Officer | 5.6yrs | US$1.89m | 0.11% $ 1.6m | |
| Vice President of Accounting & Finance | no data | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Vice President of Investor Relations | 1.2yrs | no data | no data | |
| Senior VP of Sales of North America | less than a year | no data | no data | |
| Senior VP of Marketing & Professional Relations | 3yrs | no data | no data | |
| Vice President of Human Resources | 9.4yrs | no data | no data | |
| Executive VP of Manufacturing & Commercial Operations | 3yrs | no data | no data | |
| Executive VP of Clinical & Regulatory Affairs | 2.8yrs | no data | no data |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Management: RXST's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.9yrs | US$3.08m | 2.05% $ 29.7m | |
| Director | 8.2yrs | US$204.98k | 0.11% $ 1.6m | |
| Independent Director | 3.4yrs | US$209.98k | 0.062% $ 902.7k | |
| Independent Director | 9.6yrs | US$209.98k | 0.090% $ 1.3m | |
| Independent Chairman of the Board | 10yrs | US$257.48k | 1.33% $ 19.2m | |
| Independent Director | 3yrs | US$204.98k | 0.057% $ 818.6k | |
| Independent Director | 3.4yrs | US$214.98k | 0.062% $ 902.7k | |
| Independent Director | 3.4yrs | US$212.48k | 0.062% $ 902.7k | |
| Independent Director | 3.1yrs | US$199.98k | 0.0048% $ 69.9k |
3.4yrs
Average Tenure
61yo
Average Age
Experienced Board: RXST's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 21:40 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RxSight, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Michael Gorman | BTIG |
| Xuyang Li | Jefferies LLC |